Oleogel-S10
DrugTopical gel
NCT Number: NCT06917690
The goal of this clinical trial is to learn if Oleogel-S10 gel works to treat skin wounds from two types of inherited epidermolysis bullosa (EB): junctional EB (JEB) or dystrophic EB (DEB) in the Japanese population. Children and adults may participate. The trial also looks at the safety of Oleogel-S10 gel. The main questions it will answer are:
* Does Oleogel-S10 gel close wounds from JEB or DEB within 45 days or reduce the size of the wounds? * Are there any medical problems when using Oleogel-S10 gel? * How much of the drug ends up in your blood?
The study has 2 parts. In Part 1, participants will:
* Apply Oleogel-S10 gel to the EB wound dressings at least once every 4 days for 45 days. * Visit the clinic once every 2 weeks for checkups and tests. If participants complete Part 1, they may participate in Part 2 if they choose to. In Part 2, participants will continue to receive Oleogel-S10 gel until the product is available to buy in Japan or until the trial is stopped by the company.
Interested in participating?
Request Info21 day and older
All sexes
Interventional
Phase 3
Fukuoka Children's Hospital - Dermatology, Fukuoka, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Topical gel
Time frame: Enrollment to 45 days
The number and percentage of closed wounds within Part I (up to Day 45).
Time frame: Enrollment to 90 days
Evaluations will include the proportion of participants achieving complete wound closure of at least one target wound, the change in surface area of the wound, patient and clinician impression of improvement, frequency of dressing changes, and incidence of wound infections.
Time frame: Enrollment through study completion, which is estimated for 2029
Safety will be assessed through monitoring of adverse events, physical examinations, clinical laboratory tests (blood and urine samples), and vital signs from baseline up to study completion.
Time frame: Enrollment to 45 days
The concentration of betulin in blood at baseline and on Day 45.
Contact information is provided by the study sponsor or research team.
Chiesi Farmaceutici S.p.A.
Industry
Multi-centeR, Open-label Study to EValuate the Safety, Efficacy, and Pharmacokinetics of FIlsuVEz (Oleogel-S10) in Japanese Subjects With Epidermolysis Bullosa (REVIVE)
Acronym: REVIVE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00014729
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
View Trial DetailsNCT00004791
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
View Trial DetailsNCT00004761
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
View Trial DetailsNCT06834035
Collagen Diseases, Congenital Abnormalities
Redwood City, California, United States
View Trial Details